DCA10 CRSP-CVD-400 - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
DCA10: A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
Principal Investigator
Nishant P. Shah, MD
Cardiologist
Protocol Number
IRB:
PRO00120024
NCT:
NCT07491172
Phase
Phase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment